Cited by 55Liver physiology and pathologyMesenchymal stem cell researchLiver Disease Diagnosis and Treatment

HGF and Direct Mesenchymal Stem Cells Contact Synergize to Inhibit Hepatic Stellate Cells Activation through TLR4/NF-kB Pathway

Open access
Wang, Pei-pei, Xie, Dong-ying, Liang, Xu-Jing, Peng, Liang, Zhang, Geng-lin, Ye, Yi-nong, Xie, Chan, Gao, Zhi-liang·2012·PLoS ONE

Abstract

AIMS: Bone marrow-derived mesenchymal stem cells (BMSCs) can reduce liver fibrosis. Apart from the paracrine mechanism by which the antifibrotic effects of BMSCs inhibit activated hepatic stellate cells (HSCs), the effects of direct interplay and juxtacrine signaling between the two cell types are poorly understood. The purpose of this study was to explore the underlying mechanisms by which BMSCs modulate the function of activated HSCs. METHODS: We used BMSCs directly and indirectly co-culture system with HSCs to evaluate the anti-fibrosis effect of BMSCs. Cell proliferation and activation were examined in the presence of BMSCs and HGF. c-met was knockdown in HSCs to evaluate the effect of HGF secreted by BMSCs. The TLR4 and Myeloid differentiation primary response gene 88(MyD88) mRNA levels and the NF-kB pathway activation were determined by real-time PCR and western blotting analyses. The effect of BMSCs on HSCs activation was investigated in vitro in either MyD88 silencing or overexpression in HSCs. Liver fibrosis in rats fed CCl(4) with and without BMSCs supplementation was compared. Histopathological examinations and serum biochemical tests were compared between the two groups. RESULTS: BMSCs remarkably inhibited the proliferation and activation of HSCs by interfering with LPS-TLR4 pathway through a cell-cell contact mode that was partially mediated by HGF secretion. The NF-kB pathway is involved in HSCs activation inhibition by BMSCs. MyD88 over expression reduced the BMSC inhibition of NF-kB luciferase activation. BMSCs protected liver fibrosis in vivo. CONCLUSION: BMSCs modulate HSCs in vitro via TLR4/MyD88/NF-kB signaling pathway through cell-cell contact and secreting HGF. BMSCs have therapeutic effects on cirrhosis rats. Our results provide new insights into the treatment of hepatic fibrosis with BMSCs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0043408

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [23]Sakaida I, Terai S, Nishina H, Okita K (2005) Developmentof cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol 38: 197– 202. 16378227

Cited by

Sorted by citations

Authors
Wang, P.-P., Xie, D.-Y., Liang, X.-J., Peng, L., Zhang, G.-L., Ye, Y.-N., Xie, C., & Gao, Z.-L.
Affiliations
  • Sun Yat-sen University (CN)
  • Third Affiliated Hospital of Sun Yat-sen University (CN)
Corresponding author
Xie, Chan
Venue
PLoS ONE
Published
2012-08-23
Volume
7
Issue
8
Pages
e43408
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2004568092
Cited by
55
References
34
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 3
FWCI
3.25
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Natural Science Foundation of China (H1617, 81101864)
  • Fundamental Research Funds for the Central Universities
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
bone marrow-derived mesenchymal stem cells, hepatic stellate cells, liver fibrosis, hepatocyte growth factor, c-Met, cell-cell contact, juxtacrine signaling, co-culture, MyD88, liver cirrhosis, CCl4-induced fibrosis
MeSH terms
Animals, Bone Marrow Cells, Cell Line, Dose-Response Relationship, Drug, Humans, Lipopolysaccharides, Liver Cirrhosis, Signal Transduction, Up-Regulation, NF-kappa B, Rats, Sprague-Dawley, Hepatocyte Growth Factor, Toll-Like Receptor 4, Rats, Myeloid Differentiation Factor 88, Hepatic Stellate Cells, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review